Therapeutic Asset Ratings
212 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Vofatamab
Gastric Cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(41)
Vorbipiprant
Gastric Cancer
Rottapharm Biotech
P1/2
CC
(41)
Cabotamig
Gastric Cancer
Arbele Pty Ltd
P1
CC
(40)
Cb Car-Nk18.2
Gastric Cancer
Zhejiang Provincial People's Hospital
P1
CC
(40)
Cdx-585
Gastric Cancer
Celldex Therapeutics
P1
CC
(40)
Cue-102
Gastric Cancer
Cue Biopharma
P1
CC
(40)
Imiquimod
Gastric Cancer
Toray Industries, Inc
P1
CC
(40)
ro7496353
Gastric Cancer
Genentech, Inc.
P1
CC
(40)
Zimberelimab
Gastric Cancer
Arcus Biosciences, Inc.
P1
CC
(40)
NC 410
Gastric Cancer
NextCure, Inc.
P1/2
CC
(40)
[111in]-fpi-2058
Gastric Cancer
3B Pharmaceuticals GmbH
P1
C
(37)
[111in]-fpi-2107
Gastric Cancer
AstraZeneca
P1
C
(37)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Gastric Cancer
Nurix Therapeutics, Inc.
P1
C
(37)
[225ac]-fpi-2068
Gastric Cancer
AstraZeneca
P1
C
(37)
[225]-fpi-2059
Gastric Cancer
3B Pharmaceuticals GmbH
P1
C
(37)
ab598
Gastric Cancer
Arcus Biosciences, Inc.
P1
C
(37)
ai-061
Gastric Cancer
OncoC4, Inc.
P1
C
(37)
Apg-5918
Gastric Cancer
Ascentage Pharma Group Inc.
P1
C
(37)
aur106
Gastric Cancer
Aurigene Discovery Technologies Limited
P1
C
(37)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Gastric Cancer
USWM CT, LLC
P1
C
(37)
bal0891
Gastric Cancer
SillaJen, Inc.
P1
C
(37)
bg-68501
Gastric Cancer
BeiGene
P1
C
(37)
Bgb-43395
Gastric Cancer
BeiGene
P1
C
(37)
Bl-M07D1
Gastric Cancer
SystImmune Inc.
P1
C
(37)
Bl-M17D1
Gastric Cancer
SystImmune Inc.
P1
C
(37)
Showing 126 to 150 of 212 assets
Previous
Page 6 of 9
Next
